BF
ROIV icon

BOK Financial’s Roivant Sciences ROIV Stock Holding History

BOK Financial’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,947
Closed -$338K – 1482
2024
Q2 		$338K Buy
31,947
+331
+1% +$3.63K 0.01% 672
2024
Q1 		$330K Buy
+31,616
New +$341K 0.01% 622

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

BOK Financial's ROIV Position: Q3 2024 in Review

BOK Financial sold out of Roivant Sciences (ROIV) in Q3 2024, closing a stake of 31,947 shares — an estimated $338K sold.

BOK Financial first reported a position in ROIV in Q1 2024 and held it in 2 quarters. The position peaked at $338K in Q2 2024. 293 funds tracked by Wall St. Rank hold ROIV as of Q3 2024.

  • BOK Financial reported no remaining Roivant Sciences position as of Q3 2024 after selling out during the quarter.
  • BOK Financial sold 31,947 Roivant Sciences shares in Q3 2024, an estimated $338K.
  • BOK Financial first reported a position in Roivant Sciences in Q1 2024 and held it in 2 quarters.
  • BOK Financial's Roivant Sciences position peaked at $338K in Q2 2024.
  • 293 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2024.

Based on BOK Financial's 13F filing for Q3 2024, filed 14 Nov 2024.